NBY NovaBay Pharmaceuticals Inc.

1.97
0  0%
Previous Close 1.97
Open
Price To Book 32.83
Market Cap 37,766,911
Shares 19,171,021
Volume 17,005
Short Ratio 0.2
Av. Daily Volume 3,115,909

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released August 2014. Endpoints not met
Auriclosene (NVC-422)
Viral conjunctivitis
Failed to meet endpoint Nov 2013. Plans to reinitiate trial in 2014
Auriclosene (NVC-422)
Impetigo skin infection study

Latest News

  1. NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO
  2. NovaBay's stock halted for volatility 18 times as it rockets 557%
  3. NovaBay's stock more than triples after Avenova made available on Amazon without prescription
  4. NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com
  5. NovaBay Pharmaceuticals Receives NYSE American Communication
  6. NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results
  7. NovaBay Pharmaceuticals to Hold First Quarter 2019 Conference Call on May 9, 2019
  8. NovaBay Pharmaceuticals Announces Annual Meeting of Stockholders and Receives NYSE American Communication
  9. NovaBay Pharmaceuticals Announces New Partner Pharmacy Program
  10. NovaBay Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results
  11. NovaBay Pharmaceuticals, Inc. to Host Earnings Call
  12. NovaBay Pharmaceuticals Announces Strategic Shift in U.S. Avenova Commercialization Strategy
  13. Analysts Estimate NovaBay Pharmaceuticals (NBY) to Report a Decline in Earnings: What to Look Out for
  14. NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance
  15. NovaBay Pharmaceuticals Reports Third Quarter 2018 Financial Results
  16. NovaBay Pharmaceuticals to Hold Third Quarter 2018 Conference Call on November 14, 2018
  17. Will NovaBay Pharmaceuticals (NBY) Report Negative Earnings Next Week? What You Should Know
  18. NovaBay Pharmaceuticals Names Jack McGovern Interim CEO
  19. NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6
  20. NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results